The advancements in next-generation sequencing technologies have unraveled the molecular aberrations in AML, categorizing them into several functional classes, such as signaling and kinase pathways, epigenetic modifiers, transcription factors, and tumor suppression [3] Among these, Class I (signaling and kinase pathways) exhibits the highest frequency of mutations, comprising nearly 50% of patients, with the FLT3 mutation being the most prevalent (affecting one-third of patients) [4, 5]. The gene discussed is FLT3; the disease is acute myeloid leukemia.